Thursday, June 19, 2025 5:19:35 PM
Mike, even if you're right about a referral to the CHM it doesn't mean they'll say no. I certainly have no knowledge of how they operate, but it sounded to me like they can listen to the arguments from both sides. If permitted, they could be shown evidence from early phase trials indicating that 50% or more patients could have 5-year survival with the inclusion of other therapeutics. If permitted to see such evidence, would they really be willing to delay the vaccine by several years by demanding additional trials.
I'm of the belief that all the regulators have some knowledge of what other small trials are showing. I wish they could take dynamic action and simply approve, but they won't. I do believe they'll act positively when they receive submissions to act on. I still believe we need the EDEN approval to make such submissions as approvals with production limited to 1000 patients a year make no sense for anything larger than the UK, and even there the EDEN will be needed in the not that distant future.
I still believe the likelihood of approval is well over 90%, the real question is, approval for what?
Gary
I'm of the belief that all the regulators have some knowledge of what other small trials are showing. I wish they could take dynamic action and simply approve, but they won't. I do believe they'll act positively when they receive submissions to act on. I still believe we need the EDEN approval to make such submissions as approvals with production limited to 1000 patients a year make no sense for anything larger than the UK, and even there the EDEN will be needed in the not that distant future.
I still believe the likelihood of approval is well over 90%, the real question is, approval for what?
Gary
Bullish
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
